Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.

Wallin JJ, Guan J, Prior WW, Edgar KA, Kassees R, Sampath D, Belvin M, Friedman LS.

Sci Transl Med. 2010 Sep 8;2(48):48ra66. doi: 10.1126/scitranslmed.3000630.

2.

Apoptosis induction after herpes simplex virus infection differs according to cell type in vivo.

Esaki S, Goshima F, Katsumi S, Watanabe D, Ozaki N, Murakami S, Nishiyama Y.

Arch Virol. 2010 Aug;155(8):1235-45. doi: 10.1007/s00705-010-0712-2. Epub 2010 Jun 11.

PMID:
20535504
3.

Potential therapeutic implications of cancer stem cells in glioblastoma.

Cheng L, Bao S, Rich JN.

Biochem Pharmacol. 2010 Sep 1;80(5):654-65. doi: 10.1016/j.bcp.2010.04.035. Epub 2010 May 10. Review.

4.

Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?

Kanai R, Wakimoto H, Cheema T, Rabkin SD.

Future Oncol. 2010 Apr;6(4):619-34. doi: 10.2217/fon.10.18. Review.

5.

Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.

Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK.

Neuro Oncol. 2010 Jun;12(6):559-69. doi: 10.1093/neuonc/nop058. Epub 2010 Feb 15.

6.

The PI3K pathway as drug target in human cancer.

Courtney KD, Corcoran RB, Engelman JA.

J Clin Oncol. 2010 Feb 20;28(6):1075-83. doi: 10.1200/JCO.2009.25.3641. Epub 2010 Jan 19. Review.

7.

mTOR and cancer: many loops in one pathway.

Efeyan A, Sabatini DM.

Curr Opin Cell Biol. 2010 Apr;22(2):169-76. doi: 10.1016/j.ceb.2009.10.007. Epub 2009 Nov 27.

8.

Targeting the phosphoinositide 3-kinase pathway in cancer.

Liu P, Cheng H, Roberts TM, Zhao JJ.

Nat Rev Drug Discov. 2009 Aug;8(8):627-44. doi: 10.1038/nrd2926. Review.

9.

Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Engelman JA.

Nat Rev Cancer. 2009 Aug;9(8):550-62. doi: 10.1038/nrc2664. Review.

PMID:
19629070
10.

Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.

Wakimoto H, Kesari S, Farrell CJ, Curry WT Jr, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna DS, Debasitis J, Pruszak J, Martuza RL, Rabkin SD.

Cancer Res. 2009 Apr 15;69(8):3472-81. doi: 10.1158/0008-5472.CAN-08-3886. Epub 2009 Apr 7.

11.

Regulation of the catalytic activity of herpes simplex virus 1 protein kinase Us3 by autophosphorylation and its role in pathogenesis.

Sagou K, Imai T, Sagara H, Uema M, Kawaguchi Y.

J Virol. 2009 Jun;83(11):5773-83. doi: 10.1128/JVI.00103-09. Epub 2009 Mar 18.

12.

PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.

Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC.

Cell Stem Cell. 2009 Mar 6;4(3):226-35. doi: 10.1016/j.stem.2009.01.007.

13.

Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells.

Gallia GL, Tyler BM, Hann CL, Siu IM, Giranda VL, Vescovi AL, Brem H, Riggins GJ.

Mol Cancer Ther. 2009 Feb;8(2):386-93. doi: 10.1158/1535-7163.MCT-08-0680. Epub 2009 Feb 10.

14.

Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.

Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Gillespie GY.

Mol Ther. 2009 Jan;17(1):199-207. doi: 10.1038/mt.2008.228. Epub 2008 Oct 28.

15.

Brain cancer stem cells display preferential sensitivity to Akt inhibition.

Eyler CE, Foo WC, LaFiura KM, McLendon RE, Hjelmeland AB, Rich JN.

Stem Cells. 2008 Dec;26(12):3027-36. doi: 10.1634/stemcells.2007-1073. Epub 2008 Sep 18.

16.

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions.

Visvader JE, Lindeman GJ.

Nat Rev Cancer. 2008 Oct;8(10):755-68. doi: 10.1038/nrc2499. Epub 2008 Sep 11. Review.

PMID:
18784658
17.

Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Cancer Genome Atlas Research Network.

Nature. 2008 Oct 23;455(7216):1061-8. doi: 10.1038/nature07385. Epub 2008 Sep 4. Erratum in: Nature. 2013 Feb 28;494(7438):506.

18.

An integrated genomic analysis of human glioblastoma multiforme.

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW.

Science. 2008 Sep 26;321(5897):1807-12. doi: 10.1126/science.1164382. Epub 2008 Sep 4.

19.

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.

Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, Stumm M, Cozens R, Littlewood-Evans A, García-Echeverría C, Maira SM.

Cancer Res. 2008 Aug 15;68(16):6598-607. doi: 10.1158/0008-5472.CAN-08-1044.

20.

Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis.

Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, Fulda S.

Cancer Res. 2008 Aug 1;68(15):6271-80. doi: 10.1158/0008-5472.CAN-07-6769.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk